Crisaborole topical - MC2 Therapeutics
Alternative Names: MC2 22; MC2-22 - MC2 Therapeutics; MC2-22 PAD™ CreamLatest Information Update: 27 Apr 2023
At a glance
- Originator MC2 Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Benzonitrile; Heterocyclic bicyclo compounds; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 21 Apr 2023 Preclinical trials in Atopic dermatitis in Germany (Topical) (MC2 Therapeutics pipeline, April 2023)
- 21 Apr 2023 MC2 Therapeutics plans a phase II trial for Atopic dermatitis (MC2 Therapeutics pipeline, April 2023)